138 related articles for article (PubMed ID: 8261579)
21. DT-13 synergistically enhanced vinorelbine-mediated mitotic arrest through inhibition of FOXM1-BICD2 axis in non-small-cell lung cancer cells.
Li H; Sun L; Li H; Lv X; Semukunzi H; Li R; Yu J; Yuan S; Lin S
Cell Death Dis; 2017 May; 8(5):e2810. PubMed ID: 28542137
[TBL] [Abstract][Full Text] [Related]
22. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer.
Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE
Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230
[TBL] [Abstract][Full Text] [Related]
23. Multidrug resistance-associated protein 3 and Bcl-2 contribute to multidrug resistance by vinorelbine in lung adenocarcinoma.
Hong X; Yang ZY; Wang M; Lu L; Li YH; Hao X; Chen GY
Int J Mol Med; 2011 Dec; 28(6):953-60. PubMed ID: 21874222
[TBL] [Abstract][Full Text] [Related]
24. TNF-related apoptosis-inducing ligand enhances vinorelbine-induced apoptosis and antitumor activity in a preclinical model of non-small cell lung cancer.
Zhu K; Fang W; Chen Y; Lin S; Chen X
Oncol Rep; 2014 Sep; 32(3):1234-42. PubMed ID: 25017445
[TBL] [Abstract][Full Text] [Related]
25. Vinorelbine. A review of its antitumour activity in lung cancer.
Sørensen JB
Drugs; 1992; 44 Suppl 4():60-5; discussion 66-9. PubMed ID: 1283851
[TBL] [Abstract][Full Text] [Related]
26. Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor.
Crawford J; O'Rourke MA
Semin Oncol; 1994 Oct; 21(5 Suppl 10):73-8. PubMed ID: 7526467
[TBL] [Abstract][Full Text] [Related]
27. Vinorelbine (Navelbine)--a new agent for the treatment of non-small cell lung cancer: a summary.
Coltman CA
Semin Oncol; 1994 Oct; 21(5 Suppl 10):1-3. PubMed ID: 7973763
[TBL] [Abstract][Full Text] [Related]
28. Oral administration of [3H]navelbine in patients: comparative pharmacokinetics using radioactive and radioimmunologic determination methods.
Rahmani R; Zhou XJ; Boré P; Van Cantfort J; Focan C; Cano JP
Anticancer Drugs; 1991 Aug; 2(4):405-10. PubMed ID: 1797198
[TBL] [Abstract][Full Text] [Related]
29. Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer.
Vokes EE; Rosenberg RK; Jahanzeb M; Craig JB; Gralla RJ; Belani CP; Jones SE; Bigley JW; Hohneker JA
J Clin Oncol; 1995 Mar; 13(3):637-44. PubMed ID: 7533824
[TBL] [Abstract][Full Text] [Related]
30. Vinorelbine for treatment of advanced non-small-cell lung cancer.
Med Lett Drugs Ther; 1995 Aug; 37(955):72-3. PubMed ID: 7630328
[No Abstract] [Full Text] [Related]
31. Efficacy of Navelbine (NVB) in non-small cell lung cancer (NSCLC).
Depierre A; Lemarie E; Dabouis G; Garnier G; Jacoulet P; Dalphin JC
Semin Oncol; 1989 Apr; 16(2 Suppl 4):26-9. PubMed ID: 2540532
[No Abstract] [Full Text] [Related]
32. A three-arm trial of vinorelbine (Navelbine) plus cisplatin, vindesine plus cisplatin, and single-agent vinorelbine in the treatment of non-small cell lung cancer: an expanded analysis.
Le Chevalier T; Pujol JL; Douillard JY; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S; Besson F
Semin Oncol; 1994 Oct; 21(5 Suppl 10):28-33; discussion 33-4. PubMed ID: 7973766
[TBL] [Abstract][Full Text] [Related]
33. Bayesian pharmacokinetic estimation of vinorelbine in non-small-cell lung cancer patients.
Sabot C; Marquet P; Debord J; Carpentier N; Merle L; Lachâtre G
Eur J Clin Pharmacol; 1998 Apr; 54(2):171-5. PubMed ID: 9626924
[TBL] [Abstract][Full Text] [Related]
34. Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer.
Jones S; Winer E; Vogel C; Laufman L; Hutchins L; O'Rourke M; Lembersky B; Budman D; Bigley J; Hohneker J
J Clin Oncol; 1995 Oct; 13(10):2567-74. PubMed ID: 7595708
[TBL] [Abstract][Full Text] [Related]
35. [Oral vinorelbine: pharmacology and treatment outcome in non-small cell bronchial carcinoma and breast carcinoma].
Bartsch V
Onkologie; 2006 Mar; 29 Suppl 1():1-28. PubMed ID: 16534241
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of vinorelbine in man.
Marquet P; Lachatre G; Debord J; Eichler B; Bonnaud F; Nicot G
Eur J Clin Pharmacol; 1992; 42(5):545-7. PubMed ID: 1607002
[TBL] [Abstract][Full Text] [Related]
37. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group.
J Natl Cancer Inst; 1999 Jan; 91(1):66-72. PubMed ID: 9890172
[TBL] [Abstract][Full Text] [Related]
38. Cisplatin and ifosfamide with various doses of vinorelbine (navelbine) in advanced non-small lung cancer.
Souquet PJ; Fournel P; Bohas CH; Fortune IC; Chatte G
Semin Oncol; 1996 Apr; 23(2 Suppl 5):8-10. PubMed ID: 8610239
[TBL] [Abstract][Full Text] [Related]
39. A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).
Wakelee HA; Middleton G; Dunlop D; Ramlau R; Leighl N; Hao D; Lopez-Anaya A; Zatloukal P; Jacobs CD
Cancer Chemother Pharmacol; 2012 Mar; 69(3):815-24. PubMed ID: 22057854
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of cisplatin, 5-fluorouracil, and leucovorin augmented by vinorelbine (Navelbine) for advanced non-small cell lung cancer: rationale and study design.
Vokes EE; Drinkard LC; Samuels BL; Hoffman PC; Watson S; Bitran JD; Haraf DJ; Ferguson MF; Golomb HM
Semin Oncol; 1994 Oct; 21(5 Suppl 10):79-83; discussion 83-4. PubMed ID: 7973772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
